The FDA database recorded a supplement dated 2 October 2026 to an abbreviated new drug application for generic clozapine (ANDA202873, Accord Healthcare). The record carries no detail of what the supplement changed; supplements to generic applications commonly cover manufacturing, labelling alignment or packaging.
Nothing in the record indicates a new safety finding or a change to clozapine's indication. Haematological monitoring should continue to follow local rules and the product information prescribers already use.
- No change to how clozapine is started, titrated or monitored follows from this record
- Continue neutrophil monitoring according to local requirements
- Check the current label if a patient's supply switches between generic manufacturers
Why it matters
Clozapine is the drug for treatment-resistant schizophrenia, so any regulatory movement on it is worth knowing is routine.
Don't overread it
A supplement to a generic application is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free